RT Journal Article SR Electronic T1 2022-RA-285-ESGO Real world data of treatment and outcome of patients with early ovarian cancer (FIGO I) in Germany (QS Ovar of the AGO Study Group) JF International Journal of Gynecologic Cancer JO Int J Gynecol Cancer FD BMJ Publishing Group Ltd SP A228 OP A228 DO 10.1136/ijgc-2022-ESGO.492 VO 32 IS Suppl 2 A1 Jalid Sehouli A1 Andreas du Bois A1 Jacobus Pfisterer A1 Felix Hilpert A1 Markus Kerkmann A1 Sven Mahner A1 Nikolaus de Gregorio A1 Lars Ch Hanker A1 Florian Heitz A1 Frederik Marmé A1 Linn Lena Wölber A1 Laura Holtmann A1 Sandra Polleis A1 Pauline Wimberger A1 Philipp Harter A1 AGO Study Group YR 2022 UL http://ijgc.bmj.com/content/32/Suppl_2/A228.1.abstract AB Introduction/Background Recent data regarding treatment quality and outcome of patients with early Ovarian Cancer (FIGO I) on a nationwide basis are largely missing for Germany.Methodology All German hospitals treating patients with ovarian cancer were asked to document all patients with first diagnosis in the third quarter of the years 2004, 2008, 2012 and 2016. Surgery quality was categorized as ‘optimal’ (OP+: maximum 1 parameter missing), vs ‘suboptimal’ (OP-). Chemotherapy was defined as optimal according to national guidelines. The overall treatment quality was classified in 3 categories: (1) surgery and chemotherapy optimal (OP+/CT+) versus (2) optimal/suboptimal combined (OP+/CT- or OP-/CT+) versus (3) both suboptimal (OP-/CT-).Results 19.9% (n=700) of all OC patients were diagnosed FIGO I, of which 47.1% were FIGO IA, 47.9% FIGO IC. Median follow-up period was 51.0 months. Median age was 60 years and 37.1% showed high-grade serous ovarian cancer. The OP+ collective increased from 42.2% to 70.9%. Most common not performed surgical steps were peritoneal biopsies, paraaortic and pelvic lymphadenectomy. Progression-free survival (PFS) and overall survival (OS) were improved with OP+ (84% and 91% at 48-months compared with 71% and 76% with non-optimal surgery: both p<0.001). Optimal chemotherapy standard (CT+) was administered increasingly frequent (71.4% to 80.8%). PFS and OS were prolonged with CT+: 48-months PFS 84% vs. 63% (p<0.001) and 48-months OS 90% vs. 68% (p<0.001). The overall treatment quality cohort 1 increased from 37.9% to 54.1%. 48-months PFS was 86% vs. 76% vs. 62% in group 1 vs. 2 vs. 3, respectively (p<0.001), 48-months OS rates were 93% vs. 81% vs. 68% in group 1 vs. 2 vs. 3, respectively (p<0.001).Conclusion The QS Ovar shows that the quality of therapy has steadily improved over the years in Germany. Best prognosis could be achieved if surgery and chemotherapy is done according to treatment guidelines.